 |
John W. Park, MD
John W. Park, MD is Director of Novel Therapeutics in Breast Oncology at the University of California, San Francisco (UCSF) Comprehensive Cancer and Co-Director of the UCSF Breast SPORE program. Dr. Park is also Associate Clinical Professor of Medicine and Principal Investigator in the UCSF Neuro-Oncology Program. Dr. Park received his AB in biochemical sciences from Harvard College, and his MD from Stanford University School of Medicine. He received further training in Internal Medicine at UCLA Medical Center and in Hematology-Oncology at UCSF Medical Center. Dr. Park's major research interests include novel targeted therapies of cancer, monoclonal antibody therapy, liposome- and nanoparticle-based drug delivery, and metastasis and micrometastasis. Dr. Park has been the recipient of multiple honors and awards, including the American Society of Clinical Oncology (ASCO) Young Investigator Award and the Career Development Award from the Department of Defense Breast Cancer Research Program. Dr. Park's research has been extensively published, including leading journals such as Science, Proc. Natl. Acad. Sci. USA (PNAS), Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Oncogene, Journal of Biological Chemistry, Biochemistry, Biochem. Biophys. Acta (BBA), Journal of Cell Science, Cytometry, Advances in Pharmacology, Biochemical Pharmacology, Biotechnology Progress, Journal of Controlled Release, Seminars in Oncology, Breast Cancer Research and Treatment, Breast Cancer Research, Journal of NeuroOncology, Cancer, The Cancer Journal, and Annals of Internal Medicine. In addition to his academic position, Dr. Park has extensive experience in biotechnology and drug development. Dr. Park was a postdoctoral fellow and Visiting Scientist at Genentech, Inc. from 1990 to 1995, where his research involved studies of heregulin, HER2, and the anti-HER2 monoclonal antibody trastuzumab (Herceptin®).
|
|